Oxford BioMedica PLC (OXB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oxford BioMedica PLC (OXB) has a cash flow conversion efficiency ratio of 0.072x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX2.35 Million ≈ $286.41 USD) by net assets (GBX32.73 Million ≈ $3.98K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OXB equity to assets ratio to measure how much of total assets are equity-financed.
Oxford BioMedica PLC - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Oxford BioMedica PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Oxford BioMedica PLC earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Oxford BioMedica PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oxford BioMedica PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Viet Brand Invest JSC
VN:ABR
|
N/A |
|
Traws Pharma Inc
NASDAQ:TRAW
|
0.485x |
|
Orient Press Limited
NSE:ORIENTLTD
|
0.114x |
|
NEXE Innovations Inc
V:NEXE
|
-0.026x |
|
Auplata SA
PA:ALAMG
|
0.000x |
|
NanoCMS Co. Ltd.
KQ:247660
|
0.046x |
|
Vessel Co. Ltd
KQ:177350
|
-0.209x |
|
Newport Exploration
V:NWX
|
0.092x |
Annual Cash Flow Conversion Efficiency for Oxford BioMedica PLC (1996–2024)
The table below shows the annual cash flow conversion efficiency of Oxford BioMedica PLC from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see Oxford BioMedica PLC (OXB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX60.49 Million ≈ $7.36K |
GBX-50.63 Million ≈ $-6.16K |
-0.837x | -128.45% |
| 2023-12-31 | GBX77.83 Million ≈ $9.47K |
GBX-28.52 Million ≈ $-3.47K |
-0.366x | -585.98% |
| 2022-12-31 | GBX236.19 Million ≈ $28.74K |
GBX-12.62 Million ≈ $-1.53K |
-0.053x | -139.31% |
| 2021-12-31 | GBX187.34 Million ≈ $22.79K |
GBX25.45 Million ≈ $3.10K |
0.136x | +391.64% |
| 2020-12-31 | GBX112.75 Million ≈ $13.72K |
GBX3.12 Million ≈ $379.13 |
0.028x | +159.58% |
| 2019-12-31 | GBX75.63 Million ≈ $9.20K |
GBX-3.51 Million ≈ $-426.82 |
-0.046x | -112.52% |
| 2018-12-31 | GBX34.74 Million ≈ $4.23K |
GBX12.87 Million ≈ $1.57K |
0.370x | -23.58% |
| 2017-12-31 | GBX6.15 Million ≈ $747.79 |
GBX2.98 Million ≈ $362.46 |
0.485x | +219.75% |
| 2016-12-31 | GBX12.62 Million ≈ $1.53K |
GBX-5.11 Million ≈ $-621.25 |
-0.405x | +66.39% |
| 2015-12-31 | GBX10.89 Million ≈ $1.33K |
GBX-13.12 Million ≈ $-1.60K |
-1.204x | -359.92% |
| 2014-12-31 | GBX23.04 Million ≈ $2.80K |
GBX-6.03 Million ≈ $-733.92 |
-0.262x | +78.86% |
| 2013-12-31 | GBX8.90 Million ≈ $1.08K |
GBX-11.02 Million ≈ $-1.34K |
-1.238x | -142.36% |
| 2012-12-31 | GBX19.64 Million ≈ $2.39K |
GBX-10.04 Million ≈ $-1.22K |
-0.511x | +30.06% |
| 2011-12-31 | GBX17.77 Million ≈ $2.16K |
GBX-12.98 Million ≈ $-1.58K |
-0.731x | +33.91% |
| 2010-12-31 | GBX11.61 Million ≈ $1.41K |
GBX-12.83 Million ≈ $-1.56K |
-1.105x | -1102.01% |
| 2009-12-31 | GBX20.98 Million ≈ $2.55K |
GBX2.31 Million ≈ $281.55 |
0.110x | +114.16% |
| 2008-12-31 | GBX23.27 Million ≈ $2.83K |
GBX-18.13 Million ≈ $-2.21K |
-0.779x | -626.04% |
| 2007-12-31 | GBX31.93 Million ≈ $3.89K |
GBX4.73 Million ≈ $575.50 |
0.148x | +126.02% |
| 2006-12-31 | GBX30.09 Million ≈ $3.66K |
GBX-17.13 Million ≈ $-2.08K |
-0.569x | -217.98% |
| 2005-12-31 | GBX46.60 Million ≈ $5.67K |
GBX-8.34 Million ≈ $-1.01K |
-0.179x | +54.45% |
| 2004-12-31 | GBX26.38 Million ≈ $3.21K |
GBX-10.37 Million ≈ $-1.26K |
-0.393x | -44.40% |
| 2003-12-31 | GBX35.21 Million ≈ $4.28K |
GBX-9.58 Million ≈ $-1.17K |
-0.272x | +32.51% |
| 2002-12-31 | GBX25.53 Million ≈ $3.11K |
GBX-10.30 Million ≈ $-1.25K |
-0.403x | -73.30% |
| 2001-12-31 | GBX37.51 Million ≈ $4.56K |
GBX-8.73 Million ≈ $-1.06K |
-0.233x | +38.36% |
| 2000-12-31 | GBX12.98 Million ≈ $1.58K |
GBX-4.90 Million ≈ $-596.07 |
-0.378x | +59.94% |
| 1999-12-31 | GBX3.80 Million ≈ $462.47 |
GBX-3.58 Million ≈ $-435.83 |
-0.942x | -33.06% |
| 1998-12-31 | GBX4.76 Million ≈ $579.28 |
GBX-3.37 Million ≈ $-410.27 |
-0.708x | -3219.94% |
| 1996-09-30 | GBX1.12 Million ≈ $136.88 |
GBX-24.00K ≈ $-2.92 |
-0.021x | -- |
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more